Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer.
Misako NagasakaCliff MolifeZhanglin Lin CuiVictoria StefaniakXiaohong LiSangmi KimHsui-Yung LeeJulia BeyrerGeorge BlumenscheinPublished in: Future oncology (London, England) (2022)
Aim: This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + pemetrexed + platinum (PPP) in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC), after adjusting each ORIENT-11 trial patient's contribution to ORIENT-11 data based on characteristics of a target US population. Materials & methods: The target US population (n = 557) was selected from a real-world deidentified advanced NSCLC database based on key ORIENT-11 eligibility criteria. Inverse probability weights for ORIENT-11 patients (n = 397) relative to US patients were calculated. Efficacy and safety of SPP versus PPP were adjusted by inverse probability weights. Results: After adjustment, progression-free survival remained superior for SPP. Other efficacy and safety outcomes were consistent. Conclusion: These results provide evidence on how the effects observed with SPP in ORIENT-11 could translate to a US population with untreated locally advanced/metastatic nonsquamous NSCLC.
Keyphrases
- advanced non small cell lung cancer
- small cell lung cancer
- end stage renal disease
- squamous cell carcinoma
- locally advanced
- ejection fraction
- chronic kidney disease
- epidermal growth factor receptor
- newly diagnosed
- clinical trial
- free survival
- healthcare
- peritoneal dialysis
- emergency department
- randomized controlled trial
- study protocol
- phase iii
- palliative care
- quality improvement
- machine learning
- chronic pain
- metabolic syndrome
- adipose tissue
- weight loss
- open label
- drug induced
- data analysis